Why the study?
The role of oral anticoagulation in individuals receiving dialysis with atrial fibrillation is uncertain due to exclusion from seminal trials, so this study evaluated the feasibility of a large definitive trial.
Does apixaban or warfarin compared to no oral anticoagulation demonstrate feasibility for a definitive trial in adults with nonvalvular atrial fibrillation receiving dialysis?
Population
151 adults undergoing dialysis with nonvalvular atrial fibrillation meeting CHADS-65 criteria
Comparison
Dose-adjusted warfarin vs apixaban 5 mg twice daily vs no oral anticoagulation
Design
Parallel-group open-label allocation-concealed multicenter pilot randomized controlled trial
Follow-up
26 weeks
Authors
Loading...
Confirms feasibility of large anticoagulation RCT in dialysis AF; supports definitive trial to guide therapy.
Does apixaban or warfarin compared to no oral anticoagulation demonstrate feasibility for a definitive trial in adults with nonvalvular atrial fibrillation receiving dialysis?
A pilot randomized trial demonstrated the feasibility of recruiting and maintaining adherence in dialysis patients with atrial fibrillation randomized to apixaban, warfarin, or no anticoagulation.
Harel et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: